Cowen upgraded shares of Humana (NYSE:HUM) from a market perform rating to an outperform rating in a report issued on Friday, Marketbeat reports. Cowen currently has $275.02 price target on the insurance provider’s stock.

Other analysts also recently issued reports about the company. Barclays began coverage on Humana in a research report on Thursday, September 13th. They issued an overweight rating and a $370.00 target price for the company. Morgan Stanley raised their target price on Humana from $400.00 to $418.00 and gave the stock a buy rating in a research report on Thursday, November 8th. Zacks Investment Research downgraded Humana from a buy rating to a hold rating in a research report on Monday, December 3rd. SunTrust Banks raised their target price on Humana to $380.00 and gave the stock a hold rating in a research report on Wednesday, September 19th. Finally, Jefferies Financial Group raised their target price on Humana from $388.00 to $410.00 and gave the stock a buy rating in a research report on Thursday, November 8th. Six investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $349.53.

Shares of HUM opened at $283.47 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.68 and a quick ratio of 1.68. The company has a market cap of $37.90 billion, a P/E ratio of 24.21, a price-to-earnings-growth ratio of 1.08 and a beta of 1.09. Humana has a 12 month low of $260.00 and a 12 month high of $355.88.

Humana (NYSE:HUM) last released its earnings results on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.29 by $0.29. Humana had a return on equity of 19.10% and a net margin of 2.70%. The business had revenue of $14.21 billion during the quarter, compared to the consensus estimate of $13.97 billion. During the same period last year, the business posted $3.39 earnings per share. On average, equities research analysts predict that Humana will post 14.43 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, January 25th. Stockholders of record on Monday, December 31st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.71%. The ex-dividend date is Friday, December 28th. Humana’s payout ratio is currently 8.54%.

In other news, Director David A. Jr/Ky Jones sold 600 shares of the firm’s stock in a transaction on Saturday, November 16th. The stock was sold at an average price of $88.05, for a total value of $52,830.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Heidi S. Margulis sold 2,656 shares of the firm’s stock in a transaction on Tuesday, December 18th. The stock was sold at an average price of $296.22, for a total value of $786,760.32. Following the completion of the transaction, the insider now directly owns 10,371 shares of the company’s stock, valued at $3,072,097.62. The disclosure for this sale can be found here. Insiders sold 9,078 shares of company stock valued at $2,570,350 over the last ninety days. Corporate insiders own 0.60% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. FMR LLC boosted its stake in Humana by 1.4% during the third quarter. FMR LLC now owns 12,379,797 shares of the insurance provider’s stock valued at $4,190,809,000 after buying an additional 167,283 shares during the period. BlackRock Inc. boosted its stake in Humana by 1.2% during the third quarter. BlackRock Inc. now owns 12,311,736 shares of the insurance provider’s stock valued at $4,167,767,000 after buying an additional 140,731 shares during the period. Vanguard Group Inc boosted its stake in Humana by 1.4% during the third quarter. Vanguard Group Inc now owns 10,104,225 shares of the insurance provider’s stock valued at $3,420,482,000 after buying an additional 140,864 shares during the period. Capital International Investors boosted its stake in Humana by 3,030.3% during the third quarter. Capital International Investors now owns 8,217,296 shares of the insurance provider’s stock valued at $2,781,719,000 after buying an additional 7,954,786 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Humana by 14.1% during the third quarter. Renaissance Technologies LLC now owns 3,174,800 shares of the insurance provider’s stock valued at $1,074,733,000 after buying an additional 391,300 shares during the period. 92.69% of the stock is owned by institutional investors.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Read More: Outstanding Shares

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.